Financhill
Sell
44

ATOS Quote, Financials, Valuation and Earnings

Last price:
$0.78
Seasonality move :
-7.6%
Day range:
$0.73 - $0.80
52-week range:
$0.55 - $1.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.54x
Volume:
691.1K
Avg. volume:
718.5K
1-year change:
-40.22%
Market cap:
$100.4M
Revenue:
--
EPS (TTM):
-$0.21

Analysts' Opinion

  • Consensus Rating
    Atossa Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $6.08, Atossa Therapeutics has an estimated upside of 682.83% from its current price of $0.78.
  • Price Target Downside
    According to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $0.78.

Fair Value

  • According to the consensus of 1 analyst, Atossa Therapeutics has 682.83% upside to fair value with a price target of $6.08 per share.

ATOS vs. S&P 500

  • Over the past 5 trading days, Atossa Therapeutics has underperformed the S&P 500 by -12.32% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Atossa Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Atossa Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Atossa Therapeutics reported revenues of --.

Earnings Growth

  • Atossa Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Atossa Therapeutics reported earnings per share of -$0.05.
Enterprise value:
35.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.58x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$30M -$31.3M -$28.1M -$7M -$7.4M
EBITDA -$30M -$31.2M -$28M -$7M -$7.4M
Diluted EPS -$0.22 -$0.24 -$0.21 -$0.05 -$0.05
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $141M $136.8M $110.9M $87.1M $68.7M
Total Assets $141.1M $137.5M $116.2M $91.1M $70.7M
Current Liabilities $1.4M $2.3M $2.9M $5.3M $5.4M
Total Liabilities $1.4M $2.3M $2.9M $5.3M $5.4M
Total Equity $139.7M $135.2M $113.3M $85.8M $65.3M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$22.9M -$18.6M -$22.3M -$4.7M -$6M
Cash From Investing -$4.7M -$20K -$22K -$6K -$9K
Cash From Financing -- -$1.3M $3.5M $204K --
Free Cash Flow -$22.9M -$18.6M -$22.3M -$4.7M -$6M
ATOS
Sector
Market Cap
$100.4M
$34.1M
Price % of 52-Week High
46.81%
45.43%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
-40.22%
-39.29%
Beta (5-Year)
1.013
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $0.84
200-day SMA
Sell
Level $1.06
Bollinger Bands (100)
Sell
Level 0.69 - 0.89
Chaikin Money Flow
Sell
Level -190M
20-day SMA
Sell
Level $0.87
Relative Strength Index (RSI14)
Sell
Level 43.93
ADX Line
Sell
Level 30.26
Williams %R
Buy
Level -86.1978
50-day SMA
Buy
Level $0.76
MACD (12, 26)
Buy
Level 0.01
25-day Aroon Oscillator
Buy
Level 44
On Balance Volume
Neutral
Level 987.3M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Stock Forecast FAQ

In the current month, ATOS has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ATOS average analyst price target in the past 3 months is $6.08.

  • Where Will Atossa Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Atossa Therapeutics share price will rise to $6.08 per share over the next 12 months.

  • What Do Analysts Say About Atossa Therapeutics?

    Analysts are divided on their view about Atossa Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Atossa Therapeutics is a Sell and believe this share price will drop from its current level to $4.00.

  • What Is Atossa Therapeutics's Price Target?

    The price target for Atossa Therapeutics over the next 1-year time period is forecast to be $6.08 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is ATOS A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Atossa Therapeutics is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

  • How Can I Buy Shares Of ATOS?

    You can purchase shares of Atossa Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Atossa Therapeutics shares.

  • What Is The Atossa Therapeutics Share Price Today?

    Atossa Therapeutics was last trading at $0.78 per share. This represents the most recent stock quote for Atossa Therapeutics. Yesterday, Atossa Therapeutics closed at $0.78 per share.

  • How To Buy Atossa Therapeutics Stock Online?

    In order to purchase Atossa Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Asana Stock Be in 5 Years?
Where Will Asana Stock Be in 5 Years?

Asana stock hasn’t given many investors on Wall Street any…

Where Will Dell Stock Be in 5 Years?
Where Will Dell Stock Be in 5 Years?

So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…

Where Will Cameco Stock Be in 5 Years?
Where Will Cameco Stock Be in 5 Years?

Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 47x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
82
SBET alert for May 31

SharpLink Gaming [SBET] is down 3.17% over the past day.

Buy
55
RGC alert for May 31

Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.

Buy
56
SVT alert for May 31

Servotronics [SVT] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock